Ursodeoxycholic acid (UDCA) is a naturally occurring bile acid and is used to dissolve gallstones that are rich in cholesterol. It is also used to improve the flow of bile in primary biliary cirrhosis. UDCA solubilizes cholesterol gallstones and improves the liver function in case of cholestatic diseases. UDCA can be obtained from cholic acid, which is the most abundant and least expensive bile acid available.

Increasing incidence of gallstones and cystic fibrosis is expected to propel demand for UDCA, thereby driving the ursodeoxycholic acid market growth. According to a study published in the journal Gastroenterology, 2009, cholelithiasis, the presence of gallstones in the gallbladder, is estimated to occur in 10 – 15% of the adult population in the U.S. Although, gallstones can occur at any age, it is rare before the age of 30. A progressive increase in risk of cholelithiasis is observed with age and in patients over 50, the prevalence ranges is between 25-30%.

Moreover, prevalence of gallstones is two to three times higher in women than in men. According to the American College of Gastroenterology 2018 report, gallstones occur in around 20% of women by the age of 60. Moreover, women between the age of 20 and 60 years are three times more likely to develop gallstones than men.

Furthermore, increasing research studies conducted over the applications of UCDA in other disease indications is expected to fuel growth of the global ursodeoxycholic acid market. According to the University of Sheffield August 2018 study, UDCA improves mitochondrial dysfunction, which is known to be a causative factor for both sporadic and familial Alzheimer’s disease. However, side effects associated with the use of UDCA including diarrhoea, indigestion, headache, nausea, vomiting, unusual bleeding or bruising are expected to confine growth of the market during the forecast period.

Key features of the study:

  • This report provides in-depth analysis of the global ursodeoxycholic acid market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2018 – 2026, considering 2017, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global ursodeoxycholic acid market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include, Abil Chempharma, Arcelor Chemicals, Biotavia Labs, Daewoong Chemical, Dipharma Francis, Erregierre, Grindeks, ICE, Mitsubishi Tanabe, Pharma Zell, Suzhou Tianlu, and Zhangshanbelling
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global ursodeoxycholic acid market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for ursodeoxycholic acid market, research and consulting firms, new entrants, and financial analysts